PMC:7784828 / 1622-2498 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":0,"end":142},"obj":"Sentence"},{"id":"T25","span":{"begin":143,"end":345},"obj":"Sentence"},{"id":"T26","span":{"begin":346,"end":450},"obj":"Sentence"},{"id":"T27","span":{"begin":451,"end":723},"obj":"Sentence"},{"id":"T28","span":{"begin":724,"end":733},"obj":"Sentence"},{"id":"T29","span":{"begin":734,"end":876},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The ongoing COVID-19 pandemic has imposed a heavy toll on human life, health care, global economy and almost every aspect of human life [1,2]. Yet despite its devastating effects, it has also mobilized and united many elements of the drug discovery and development process to seek therapies to address this most pressing public health emergency. In a record time frame, 36 vaccines have entered in clinical trials and 89 are in preclinical phase [3]. While it usually takes 10–15 years to develop a vaccine, in less than a year, promising results from phase III clinical trials of the Pfizer/BioNTech vaccine were recently announced with results from trials by other pharma companies expected to follow soon (Figure 1) [4].\nFigure 1. Comparison between the traditional vaccine development timeline and the accelerated development time line in response to the COVID-19 pandemic"}

{"project":"LitCovid-PubTator","denotations":[{"id":"3","span":{"begin":859,"end":867},"obj":"Disease"},{"id":"7","span":{"begin":58,"end":63},"obj":"Species"},{"id":"8","span":{"begin":125,"end":130},"obj":"Species"},{"id":"9","span":{"begin":12,"end":20},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"Tax:9606"},{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"Tax:9606"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The ongoing COVID-19 pandemic has imposed a heavy toll on human life, health care, global economy and almost every aspect of human life [1,2]. Yet despite its devastating effects, it has also mobilized and united many elements of the drug discovery and development process to seek therapies to address this most pressing public health emergency. In a record time frame, 36 vaccines have entered in clinical trials and 89 are in preclinical phase [3]. While it usually takes 10–15 years to develop a vaccine, in less than a year, promising results from phase III clinical trials of the Pfizer/BioNTech vaccine were recently announced with results from trials by other pharma companies expected to follow soon (Figure 1) [4].\nFigure 1. Comparison between the traditional vaccine development timeline and the accelerated development time line in response to the COVID-19 pandemic"}